FY2025 · ended Dec 31, 2025 · Revenue $294.28M, +64.1% YoY · Filed Mar 3, 2026
Rigel Pharmaceuticals Inc (RIGL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $294.3 million and net income of $367.0 million. As of Sep 30, 2026 it held $120.7 million in cash and investments and $556,000 in total debt.
Revenue (TTM)
$288.21M
+2.2% vs year-ago TTM
Net income (TTM)
$307.19M
+171.1% vs year-ago TTM
Operating cash flow (TTM)
$89.92M
+31.9% vs year-ago TTM
Free cash flow
$-74.21M
-1513.2% vs prior year
EPS (TTM)
$15.38
+148.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
18.47M
+3.4% vs prior year
Net cash
$120.15M
as of Sep 30, 2026
Operating margin
26.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RIGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1034842
- Former names
- RIGEL PHARMACEUTICALS INC (until Nov 5, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M |
| Diluted EPS | $19.48 | $0.99 | -$1.44 | -$3.44 | -$0.11 |
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M |
| Free cash flow | — | — | — | -$74.2M | $5.3M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | — |
| Stockholders' equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M |
| Cash and investments | $155.0M | $77.3M | $56.9M | $58.2M | $125.0M |
| Total debt | $53.5M | $60.3M | $61.0M | $42.1M | $30.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Acquisition or sale of assets
|
Jun 17, 2026 | Jun 11, 2026 |
All 1002 Rigel Pharmaceuticals Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.